Springer Seminars in Immunopathology

, Volume 26, Issue 1–2, pp 57–69 | Cite as

Non-myeloablative stem cell transplantation for autoimmune diseases

  • Richard K. BurtEmail author
  • Larissa Verda
  • Yu Oyama
  • Laisvyde Statkute
  • Shimon Slavin
Original Paper


Treatment of life-threatening autoimmune diseases in animal models with induced or spontaneous autoimmune diseases can be accomplished by a 2-step procedure involving elimination of self-reactive lymphocytes with an immune ablative conditioning regimen followed by infusion of autologous or allogeneic stem cells, respectively. In animal models it was shown that using such a strategy, autoimmunity could be adequately controlled. It is speculated that de-novo development of the T and B cell repertoire from uncommitted progenitor cells in the presence of the autoantigens may be the best recipe for re-induction of self-tolerance, similarly to the normal ontogeny of the immune system during the induction of self tolerance in fetal stage. For both autologous and allogeneic hematopoietic stem cell transplantation, a non-myeloablative stem cell transplantation (NST) regimen may be used for safer lymphoablation rather than myeloablation. In addition, for allogeneic hematopoietic stem cell transplantation engraftment of disease resistant donor stem cells will alter the genetic predisposition towards autoimmune disease susceptibility.


Non-myeloablative stem cell transplantation Systemic lupus erythematosus Multiple sclerosis Scleroderma Rheumatoid arthritis 


  1. 1.
    Abu-Shakra M, Lee P (1993) Exaggerated fibrosis in patients with systemic sclerosis (scleroderma) following radiation therapy. J Rheumatol 20:1601Google Scholar
  2. 2.
    Abu-Shakra M, Lee P (1995) Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol 22:2100Google Scholar
  3. 3.
    Altman RD, Medsger TA, Bloch DA, et al (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403Google Scholar
  4. 4.
    Baldwin JL, Storb R, Thomas ED, et al (1977) Bone marrow transplantation in patients with gold-induced marrow aplasia. Arthritis Rheum 20:1043Google Scholar
  5. 5.
    Beebe AM, Cua DJ, Waal Malefyt R de (2002) The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev 13:403Google Scholar
  6. 6.
    Behan PO (2002) The pathogenesis of multiple sclerosis revisited. J R Coll Physians Edinb 32:244Google Scholar
  7. 7.
    Bombardier C, Gladman DD, Urowitz MB, et al (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630Google Scholar
  8. 8.
    Burt RK (2004) Hematopoietic stem cell therapy for patients with refractory myasthenia gravis. In: Burt RK, Marmont A (eds) Stem cell therapy for autoimmune diseases. Landes Bioscience, Georgetown, pp 428–432Google Scholar
  9. 9.
    Burt RK, Barr W, Pope R, et al (2004) The rationale behind the design of autologous autoimmune hematopoietic stem cell transplant regimens: concerns over the role of total body irradiation in scleroderma. Bone Marrow Transplant (in press)Google Scholar
  10. 10.
    Burt RK, Burns W, Hess A (1995) Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant 16:1Google Scholar
  11. 11.
    Burt RK, Cohen BA, Russell E, et al (2003) Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 102:2373Google Scholar
  12. 12.
    Burt RK, Fassas A, Snowden JA, et al (2001) Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant 28:1Google Scholar
  13. 13.
    Burt RK, Georganas C, Schroeder J, et al (1999) Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis: sustained response in two of four patients. Arthritis Rheum 42:2281Google Scholar
  14. 14.
    Burt RK, Oyama Y, Verda L, et al (2004) Remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism. Arthritis Rheum (in press)Google Scholar
  15. 15.
    Burt RK, Slavin S, Burns W, Marmont A (2002) Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation. Blood 99:768Google Scholar
  16. 16.
    Burt RK, Traynor A, Oyama Y, et al (2003) High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood 101:2064Google Scholar
  17. 17.
    Burt RK, Traynor A, Ramsey-Goldman R (1997) Hematopoietic stem cell transplantation for systemic lupus erythematosus. N Engl J Med 337:1777Google Scholar
  18. 18.
    Burt RK, Traynor AE, Cohen B, et al (1998) T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 21:537Google Scholar
  19. 19.
    Burt RK, Traynor AE, Pope R, et al (1998) Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 92:3505Google Scholar
  20. 20.
    Cash JM, Wilder RL (1995) Treatment-resistant rheumatic disease. Rheum Dis Clin N Am 21:1Google Scholar
  21. 21.
    Cohen Y, Polliack A, Nagler A (2003) Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and/or high dose chemotherapy with hematopoietic stem cell support. Curr Pharm Des 9:279Google Scholar
  22. 22.
    Confavreux C, Vukusic S, Moreau T et al (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430Google Scholar
  23. 23.
    Drakos PE, Nagler A, Or R (1993) Case of Crohn’s disease in bone marrow transplantation Am J Hematol 43:157–158Google Scholar
  24. 24.
    Erhardt CC, Mumford PA, Venables PJ, et al (1989) Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 48:7Google Scholar
  25. 25.
    Farge D, Marolleau JP, Zohar S, et al (2002) Intensification et Autogreffe dans les Maladies Auto Immunes Resistantes (ISAMAIR) Study Group. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 119:726Google Scholar
  26. 26.
    Farmer RG, Whelan G, Fazio VW (1985) Long-term follow-up of patients with Crohn’s disease. Relationship of clinical pattern and prognosis. Gastroenterology 88:1818Google Scholar
  27. 27.
    Fassas A, Anagnostopoulos A, Kazis A, et al (1997) Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 20:631Google Scholar
  28. 28.
    Fassas A, Anagnostopoulos A, Kazis A, et al (2000) Autologous stem cell transplantation in progressive multiple sclerosis—an interim analysis of efficacy. J Clin Immunol 20:24Google Scholar
  29. 29.
    Graham-Brown RA, Sarkany I (1983) Scleroderma-like changes due to chronic graft-versus-host disease. Clin Exp Dermatol 8:531Google Scholar
  30. 30.
    Hietarinta M, Koskimies S, Lassila O, et al (1993) Familial scleroderma: HLA antigens and autoantibodies. Br J Rheumatol 32:336Google Scholar
  31. 31.
    Ikehara S, Good RA, Nakamura T, et al (1985) Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci USA 82:2483Google Scholar
  32. 32.
    Ikehara S, Ohtsuki H, Good RA, et al (1985) Prevention of type I diabetes in nonobese diabetic mice by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 82:7743Google Scholar
  33. 33.
    Joske DJ, Ma DT, Langlands DR, et al (1997) Autologous bone-marrow transplantation for rheumatoid arthritis. Lancet 350:337Google Scholar
  34. 34.
    Karussis DM, Slavin S, Ben-Nun A, et al (1992) Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation. J Neuroimmunol 39:201Google Scholar
  35. 35.
    Kashyap A, Passweg J, Tyndall A (2001) Autologous stem cell transplant regimens for the treatment of severe autoimmune diseases. In: Autologous blood and marrow transplantation: proceedings of the tenth international symposium Dallas, Texas. Carden Jennings Publishing, Charlottesville, pp 219–225Google Scholar
  36. 36.
    Kozak T, Havrdova E, Pitha J, et al (2000) High-dose immunosuppressive therapy with PBSC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 25:525Google Scholar
  37. 37.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an extended disability status scale (EDSS). Neurology 33:1444Google Scholar
  38. 38.
    Liossis SN, Tsokos GC (2000) Systemic lupus erythematosus. In: Principles of molecular rheumatology. Humana Press, Totowa, pp 311–323Google Scholar
  39. 39.
    Mancardi GL, Saccardi R, Filippi M, et al (2001) Autologous hematopoietic stem cell transplantation suppresses gd-enhanced MRI activity in MS. Neurology 57:62Google Scholar
  40. 40.
    Marmont AM (1993) Immune ablation with stem-cell rescue: a possible cure for systemic lupus erythematosus? Lupus 2:151Google Scholar
  41. 41.
    Marmont AM, Lint MT van, Gualandi F, et al (1997) Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus 6:545Google Scholar
  42. 42.
    McSweeney PA, Nash RA, Sullivan KM, et al (2002) High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100:1602Google Scholar
  43. 43.
    Mielczarek M, Storb R (2003) Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies. Cancer Treat Rev 29:283Google Scholar
  44. 44.
    Monje ML, Mizumatsu S, Fike JR, et al (2002) Irradiation induces neural precursor-cell dysfunction. Nat Med 8:955Google Scholar
  45. 45.
    Morton JI, Siegel BV (1979) Transplantation of autoimmune potential. IV. Reversal of the NZB autoimmune syndrome by bone marrow transplantation. Transplant 27:133Google Scholar
  46. 46.
    Nash RA, Bowen JD, McSweeney PA, et al (2003) High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102:2364Google Scholar
  47. 47.
    Openshaw H, Stuve O, Antel JP, et al (2000) Multiple sclerosis flares associated with recombinant granulocytes colony-stimulating factor. Neurology 54:2147Google Scholar
  48. 48.
    Pestronk A, Drachman DB, Teoh R, et al (1983) Combined short-term immunotherapy for experimental autoimmune myasthenia gravis. Ann Neurol 14:235Google Scholar
  49. 49.
    Renga M, Pedrazzoli P, Siena S (2003) Present results and perspectives of allogeneic non-myeloablative hematopoietic stem transplantation for treatment of human solid tumors. Ann Oncol 14:1177Google Scholar
  50. 50.
    Silman AJ, Black CM, Welsh KI (1996) Epidemiology, demographics, genetics. In: Systemic sclerosis. Williams & Wilkins, Baltimore, pp 23–50Google Scholar
  51. 51.
    Slavin S (2002) Non-myeloablative stem cell transplantation for induction of host-versus-graft tolerance for adoptive immunotherapy of malignant and nonmalignant diseases and towards transplantation of organ allografts. Transplant Proc 34:3371Google Scholar
  52. 52.
    Slavin S (1979) Successful treatment of autoimmune disease in (NZB/NZW)F1 female mice by using fractionated total lymphoid irradiation. Proc Natl Acad Sci USA 76:5274Google Scholar
  53. 53.
    Slavin S (1993) Treatment of life threatening autoimmune diseases with myeloablative doses of immunosuppressive agents and autologous bone marrow transplantation—rationale and experimental background. Bone Marrow Transplant 12:85Google Scholar
  54. 54.
    Slavin S, Morecki S, Weiss L, et al (2003) Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Crit Rev Oncol Hematol 46:139Google Scholar
  55. 55.
    Slavin S, Nagler A, Varadi G, et al (2000) Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 28:853Google Scholar
  56. 56.
    Takeuchi K, Inaba M, Miyashima S, et al (1998) A new strategy for treatment of autoimmune diseases in chimeric resistant MRL/lpr mice. Blood 91:4616Google Scholar
  57. 57.
    Traynor AE, Barr WG, Rosa RM, et al (2002) Hematopoietic stem cell transplantation for severe and refractory lupus. Arthritis Rheum 46:2917Google Scholar
  58. 58.
    Traynor AE, Schroeder J, Rosa RM, et al (2000) Treatment of severe systemic lupus with high dose intense chemotherapy and hematopoietic stem cell transplantation: a phase I study. Lancet 356:701Google Scholar
  59. 59.
    Tyndall A, Black C, Finke J, et al (1997) Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet 349:254Google Scholar
  60. 60.
    Van Bekkum DW, Bohre EP, Houben PF, et al (1989) Regression of adjuvant-induced arthritis in rats following bone marrow transplantation. Proc Natl Ac Sci USA 86:10090Google Scholar
  61. 61.
    Vaughan D, Drumm B (1999) Treatment of fistulas with granulocytes colony-stimulating factor in a patient with Crohn’s disease. N Engl J Med 340:239Google Scholar
  62. 62.
    White B, Moore WC, Wigley FM, et al (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Int Med 132:947Google Scholar
  63. 63.
    Willenborg DO, Staykova MA (2003) Cytokines in the pathogenesis and therapy of autoimmune encephalomyelitis and multiple sclerosis. In: Santamaria P (ed) Cytokines and chemokines in autoimmune disease. and Kluwer Acad/Plenum Publishers, New York, pp 97–116Google Scholar
  64. 64.
    Wolfe F, Mitchell DM, Sibley JT, et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481Google Scholar
  65. 65.
    Wulffraat N, Royen A van, Bierings M, et al (1999) Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet 353:550Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Richard K. Burt
    • 1
    Email author
  • Larissa Verda
    • 1
  • Yu Oyama
    • 1
  • Laisvyde Statkute
    • 1
  • Shimon Slavin
    • 2
  1. 1.Division of ImmunotherapyNorthwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Department of Bone Marrow Transplantation and Cancer ImmunotherapyHadassah UniversityJerusalemIsrael

Personalised recommendations